SCI时时刷

search
+
Immunogenetics in hematopathology and hematology: why a common language is important
Immunogenetics in hematopathology and hematology: why a common language is important
IMGT-ONTOLOGY: standardization of immunogenetic nomenclatureOne of the most important aspects in the implementation of imm...
8-Cl-Ado and 8-NH2-Ado synergize with venetoclax to target the methionine-MAT2A-SAM axis in acute myeloid leukemia
8-Cl-Ado and 8-NH2-Ado synergize with venetoclax to target the methionine-MAT2A-SAM axis in acute myeloid leukemia
Targeting the metabolic dependencies of acute myeloid leukemia (AML) cells is a promising therapeutical strategy. In parti...
Measurable residual disease (MRD)-testing in haematological and solid cancers
Measurable residual disease (MRD)-testing in haematological and solid cancers
Li MC, Hertz R, Bergenstal DM. Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine anta...
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer
Clonal hematopoiesis (CH) driven by mutations in the DNA damage response (DDR) pathway is frequent in patients with cancer...
Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine in acute myeloid leukemia
Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine in acute myeloid leukemia
The hypomethylating agent 5-azacytidine (AZA) is the first-line treatment for AML patients unfit for intensive chemotherap...
Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms
Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms
Somatic mutations in the splicing factor SF3B1 occur in about one-third of all myelodysplastic neoplasms (MDS) and define ...
Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation
Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation
Relapse remains a key cause of transplant failure in high-risk B-cell acute lymphoblastic leukemia (B-ALL). Nevertheless, ...
KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia
KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia
These authors contributed equally: Shinju Iyoda, Kenichi Yoshida, Kota Shoji.Human Health Sciences, Graduate School of Med...
Correction to: Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors
Correction to: Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors
Authors and AffiliationsDana-Farber Cancer Institute, Boston, MA, USAJooeun Bae, Teru Hideshima, Yu-Tzu Tai, Yan Song, Pau...
Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression
Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression
TNF receptor associated factor 6 (TRAF6) is an E3 ubiquitin ligase that has been implicated in myeloid malignancies. Altho...
Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations
Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations
Despite significant progress in chronic myeloid leukemia (CML) therapy over recent decades, the blast crisis (BC) remains ...
Fluorescence in situ hybridization reveals the evolutionary biology of minor clone of gain/amp(1q) in multiple myeloma
Fluorescence in situ hybridization reveals the evolutionary biology of minor clone of gain/amp(1q) in multiple myeloma
Growing evidence suggests that gain or amplification [gain/amp(1q)] accumulates during disease progression of multiple mye...
Genome-wide DNA methylation-analysis of blastic plasmacytoid dendritic cell neoplasm identifies distinct molecular features
Genome-wide DNA methylation-analysis of blastic plasmacytoid dendritic cell neoplasm identifies distinct molecular features
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) constitutes a rare and aggressive malignancy originating from plasmac...
Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia
Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia
The emergence of next generation sequencing and widespread use of mutational profiling in acute myeloid leukemia (AML) has...
Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia
Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia
Due to the rarity of TP53 mutations in acute lymphoblastic leukemia (ALL), p53 re-activation by antagonism of the p53-MDM2...
Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures
Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures
The immediate goal for therapy in patients with systemic immunoglobulin light chain amyloidosis (AL) ...
Pre-frailty after blood or marrow transplantation and the risk of subsequent mortality
Pre-frailty after blood or marrow transplantation and the risk of subsequent mortality
We examined the prevalence, risk factors, and association between pre-frailty and subsequent mortality after blood or marr...
High-plex imaging and cellular neighborhood spatial analysis reveals multiple immune escape and suppression patterns in diffuse large B-cell lymphoma
High-plex imaging and cellular neighborhood spatial analysis reveals multiple immune escape and suppression patterns in diffuse large B-cell lymphoma
A hallmark of hematological malignancies such as diffuse large B-cell lymphoma (DLBCL) is heterogeneity, with contribution...
IκBε deficiency accelerates disease development in chronic lymphocytic leukemia
IκBε deficiency accelerates disease development in chronic lymphocytic leukemia
The NFKBIE gene, which encodes the NF-κB inhibitor IκBε, is mutated in 3–7% of patients with chronic ...
Loss of hematopoietic progenitors heterogeneity is an adverse prognostic factor in lower-risk myelodysplastic neoplasms
Loss of hematopoietic progenitors heterogeneity is an adverse prognostic factor in lower-risk myelodysplastic neoplasms
Myelodysplastic neoplasms (MDS) are characterized by clonal evolution starting from the compartment of hematopoietic stem ...
The role of quiescent thymic progenitors in TAL/LMO2-induced T-ALL chemotolerance
The role of quiescent thymic progenitors in TAL/LMO2-induced T-ALL chemotolerance
Relapse in T-cell acute lymphoblastic leukemia (T-ALL) may signify the persistence of leukemia-initiating cells (L-ICs). E...
A complex interplay of intra- and extracellular factors regulates the outcome of fetal- and adult-derived MLL-rearranged leukemia
A complex interplay of intra- and extracellular factors regulates the outcome of fetal- and adult-derived MLL-rearranged leukemia
Infant and adult MLL1/KMT2A-rearranged (MLLr) leukemia represents a disease with a dismal prognosis. Here, we present a fu...
Mitigating immortal-time bias: exploring osteonecrosis and survival in pediatric ALL - AALL0232 trial insights
In this issue, Mattano et al. report on the development of osteonecrosis among patients with acute lymphoblastic leukemia ...
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry
Blast phase (BP) of chronic myeloid leukemia (CML) still represents an unmet clinical need with a dismal prognosis. Due to...
Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?
Kantarjian H, Jabbour E, Cortes J. Chronic Myeloid Leukemia. In: Loscalzo J, Fauci A, Kasper D, Hauser S, et al., editors....
Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy
Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy
The use of Hypomethylating agents combined with Venetoclax (VH) for the treatment of Acute Myeloid Leukemia (AML) has grea...
ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?
ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?
There is a high risk of GVHD and non-relapse mortality (NRM) after allogeneic stem cell transplantations (alloSCT) from un...
Radiotherapy in younger patients with advanced aggressive B-cell lymphoma—long-term results from the phase 3 R-MegaCHOEP trial
Radiotherapy in younger patients with advanced aggressive B-cell lymphoma—long-term results from the phase 3 R-MegaCHOEP trial
The role of consolidative radiotherapy (RT) for patients with aggressive B-cell lymphoma has not been fully elucidated. Th...
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients
The clinical impact of molecular ontogeny in acute myeloid leukemia (AML) was defined in patients treated with intensive c...
Clonal hematopoiesis and its impact on the aging osteo-hematopoietic niche
Clonal hematopoiesis and its impact on the aging osteo-hematopoietic niche
Clonal hematopoiesis (CH) defines a premalignant state predominantly found in older persons that increases the risk of dev...
阅读更多
format_indent_increase